Novo Nordisk has unveiled promising new findings from its OASIS 4 phase 3 trial. The findings suggest that a daily Wegovy weight-loss pill could serve as a highly effective alternative to the widely used injectable formulation. The pharmaceutical giant’s latest data indicates that the oral version of the drug may offer a more accessible route for patients managing obesity. This…